The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | L | Antineoplastic and immunomodulating agents | |
| 2 | L04 | Immunosuppressants | |
| 3 | L04A | Immunosuppressants | |
| 4 | L04AA | Selective immunosuppressants | |
| 5 | L04AA06 | Mycophenolic acid |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| ORAL - Oral | 2 g |
| PAREN - Parenteral | 2 g |
| Active Ingredient | Description | |
|---|---|---|
| Mycophenolate mofetil |
Mycophenolate mofetil is the 2-morpholinoethyl ester of mycophenolic acid (MPA). MPA is a potent, selective, uncompetitive and reversible inhibitor of inosine monophosphate dehydrogenase, and therefore inhibits the de novo pathway of guanosine nucleotide synthesis without incorporation into DNA. |
|
| Mycophenolic acid |
Mycophenolic acid is a potent, selective, uncompetitive and reversible inhibitor of inosine monophosphate dehydrogenase, and therefore inhibits the de novo pathway of guanosine nucleotide synthesis without incorporation into DNA. Mycophenolic acid has more potent cytostatic effects on lymphocytes than on other cells and is indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in adult patients receiving allogeneic renal transplants. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| CELLCEPT Capsules, hard | European Medicines Agency (EU) | MPI, EU: SmPC | |
| CELLCEPT Powder for concentrate for solution for infusion | European Medicines Agency (EU) | MPI, EU: SmPC | |
| CEPTAVA Gastro-resistant tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
| MYCLAUSEN Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
| MYCOKEM 500 Film-coated tablet | Pharmaceutical Benefits Scheme (AU) | MPI, EU: SmPC | |
| MYFORTIC Gastro-resistant tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
